title: Direct effects of growth hormone on production and secretion of apolipoprotein B from rat hepatocytes.
abstract: The aim of this study was to investigate the direct effects of growth hormone (GH) on production and secretion of apolipoprotein B (apoB)-containing lipoproteins from hepatocytes. Bovine GH (5-500 ng/ml) was given for 1 or 3 days to rat hepatocytes cultured on laminin-rich matrigel in serum-free medium. The effects of GH were compared with those of 3 nM insulin and 500 microM oleic acid. GH increased the editing of apoB mRNA, and the proportion of newly synthesized apoB-48 (of total apoB) in the cells and secreted into the medium changed in parallel. GH increased total secretion of apoB-48 (+30%) and apoB-48 in very low density lipoproteins (VLDL) more than twofold. Total apoB-100 secretion decreased 63%, but apoB-100-VLDL secretion was unaffected by GH. Pulse-chase studies indicated that GH increased intracellular early degradation of apoB-100 but not apoB-48. GH had no effect on apoB mRNA or LDL receptor mRNA levels. The triglyceride synthesis, the mass of triglycerides in the cells, and the VLDL fraction of the medium increased after GH incubation. Three days of insulin incubation had effects similar to those of GH. Combined incubation with oleic acid and GH had additive effects on apoB mRNA editing and apoB-48-VLDL secretion. In summary, GH has direct effects on production and secretion of apoB-containing lipoproteins, which may add to the effects of hyperinsulinemia and increased flux of fatty acids to the liver during GH treatment in vivo.
authors.affiliation: Department of Physiology, Goteborg University, S-405 30 Goteborg, Sweden.
authors.forename: D
authors.initials: D
authors.lastname: Lindén
authors.forename: A
authors.initials: A
authors.lastname: Sjöberg
authors.forename: L
authors.initials: L
authors.lastname: Asp
authors.forename: L
authors.initials: L
authors.lastname: Carlsson
authors.forename: J
authors.initials: J
authors.lastname: Oscarsson
mesh_terms: D000818:Animals; D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D001055:Apolipoproteins B / Q000235:genetics* / Q000378:metabolism*; D002478:Cells, Cultured; D005260:Female; D015870:Gene Expression / Q000187:drug effects / Q000502:physiology; D013006:Growth Hormone / Q000494:pharmacology*; D022781:Hepatocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D008079:Lipoproteins, VLDL / Q000378:metabolism; D019301:Oleic Acid / Q000494:pharmacology; D017393:RNA Editing / Q000502:physiology; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D011973:Receptors, LDL / Q000235:genetics; D014280:Triglycerides / Q000096:biosynthesis
chemical_list: D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D001055:Apolipoproteins B; D007004:Hypoglycemic Agents; D007328:Insulin; D008079:Lipoproteins, VLDL; D012333:RNA, Messenger; D011973:Receptors, LDL; D014280:Triglycerides; D019301:Oleic Acid; D013006:Growth Hormone